Sichuan was the first to announce 25 varieties of payment standards brought about five major impacts

September 24th, the Sichuan Medical Insurance Bureau issued a public consultation on the issuance of a notice (draft for comments) on the issuance of a notice on the centralized procurement and use of drugs by state organizations to expand the standards for payment of medical insurance for related drugs. In the annex section, Sichuan Province announced the state-organized centralized procurement and use of drugs to expand the relevant drug medical insurance payment standards, around 25 drugs, Sichuan for different pharmaceutical companies, different product regulations of 503 drugs set payment standards. In its circular, Sichuan noted that the payment criteria apply to 25 drugs, including selected and non-selected drugs, that have been expanded through the centralized procurement and use of drugs organized by the State. That is to say, whether it is the selected or non-selected varieties, you need to refer to this standard for medical insurance reimbursement.Why Sichuan? We believe that, first, because of the large number of insured people in Sichuan Province, the pilot of the province's unified standard of medical insurance payment, the number of people appear to have weight. Second, because the national level of the southwest region health care reform linkage has great expectations, such as the southwest five provinces cross-regional outpatient settlement, such as long-term care insurance pilot here have a lot of forward-looking, in-depth pilot. Third, because from a central and western provinces with basic representative, from the provincial health insurance payment standards to the national provinces are reference to the formulation of provincial health insurance payment standards, Sichuan Province is basically in the middle zone, can radiate to other regions.In this paper, we discuss some of the practical effects of this new policy in Sichuan, especially on the collection of non-chinese drug companies.

Sichuan Province to take the lead in developing provincial health insurance payment standards, we believe that the main impact has five aspects:First, Sichuan's first batch of 25 varieties of national collection to develop payment standards, showing a stable foundation, broad prospects. These 25 varieties were collected by the state relatively early and have an advantage in time, are also used in the use of the pilot expansion of the drug, in the dosing and release of the need, but also through consistent evaluation, in the technical standards, in general, more incentives for pharmaceutical companies involved.Second, the medical insurance department to develop a unified standard of medical insurance payment, for pharmaceutical companies to lose a piece of the game hinterland. Whether or not the varieties of pharmaceutical enterprises are included in the scope of national collection, provincial and municipal procurement, regardless of whether pharmaceutical enterprises to participate in the collection of competition enthusiasm or indifference, the unified standard of medical insurance payment is there. You reject it by abandoning the health insurance market, and pharmaceutical companies are going the other way.Third, the medical insurance drug catalog is no longer all pharmaceutical companies to squeeze the head to enter, after entering is no longer a safe nest. Because the National Health Insurance Administration and other nine departments issued "on the national organization of drug centralized procurement and use of the pilot expansion of regional scope of implementation opinion" has clearly stated that the same generic name of the drug in principle applicable to the same payment standards, early into the evening, into the north and south of Rener.Previously, the State Health Insurance Administration and other nine departments issued "on the national organization of drug centralized procurement and use of the pilot expansion of regional scope of implementation opinion" clearly pointed out that the exploration of centralized procurement of pharmaceutical medical insurance payment standards and procurement price synergy. "For centralizedly procured drugs, the medical insurance fund shall, in principle, settle the same payment standards for the original research drugs, the evaluation preparations, and generic drugs evaluated by consistency within the scope of the medical insurance catalogue with the centralized purchase price as the standard for payment of medical insurance." Patients use drugs higher than the payment standard, the part of the payment standard is paid by the patient, such as the patient's drug price and the selected drug centralized purchase price difference is large, can gradually adjust the payment standard, adjust in place within 2-3 years, and formulate supporting policy measures; On the basis of ensuring quality and supply, medical institutions and patients are guided to form reasonable drug habits. Where a fixed-point retail pharmacy of medical insurance participates in this purchase, it may be allowed to increase the price appropriately on the basis of the selected price, and the portion that exceeds the payment standard shall be paid by the patient, and the following part of the payment standard shall be reimbursed by the medical insurance in accordance with the provisions".Fourth, in deepening medical reform, the recruitment represented by the collection, as well as the payment reform represented by the payment standard. The influence between the two is gradually transformed, collecting tools are good at finding prices through market competition, in the actual operation of fish leakage, payment standards are longer than system protection, both to adjust the pharmaceutical industry, protect health insurance funds, patients' consumer rights and interests.Fifth, it is foreseeable that the standard of payment for health insurance will become more widely covered, more and more invincible and transparent. The development of payment standards itself is a very controversial thing, between pharmaceutical companies, public opinion supervision from one to the next. But as long as the determination is greater than worry, you can immediately find a lot of reference systems, such as industry data, business advice, academic research and so on. Payment standards are accepted by society.

for the collection of non-selecting enterprises, we think that basically only these options are left:One is mo fist rub, waiting in the next collection to fight hard for the election. This is not impossible, there is a saying called "first fat is not fat", do not look at the national drug collection has been carried out three batches, the first three batch of selected enterprises are not all clear strategic support "win", these pharmaceutical companies also have internal disputes. At present, the drug companies that have not been selected in the unelested track suffered a new blow, may also further change the mentality, but also want to hold tickets in the left hand, right hand with the end of the hospital promotion, two-pronged, stay in the market do not do change.Second, Mingshing Road, seize the health insurance, non-medical insurance, international B2B market. Unso selected pharmaceutical companies can immediately reduce the price of the affected areas of the internet, this is not the first to eat crabs, there have been previous examples. If at the same time outside Sichuan to open a sharp reduction in the price of hanging net, will undoubtedly be on the list of industry hot search, but also become a health care reform policy, landing supervision department's heart is good, in the domestic health insurance, non-medical insurance market will be a "cut" to become famous. More importantly, the non-chinese drug companies can consider going out to sea, once on the high seas will be calmer.Third, broken cans, simply be merged, transferred, by secondary entrepreneurship. In the new era of mass entrepreneurship and innovation, even the health insurance policy department, the comprehensive medical reform department can not sit still, for the sale of gold, drug prices inflated can be said to be frequent knife, knife and blood, aggressive, the old road has been broken. Part of the most open, but also the most failed pharmaceutical companies can imitate the health hall, farmer mountain spring, since the medicine can not touch, simply do health care products, do the concept of quick-kill. There is the equivalent of Science, net red plate, on the courage to eat.Provincial health insurance payment standards, not too soon, but too late, has been arrow in the string, had to send the point. Relevant policy research has long been laid out, Sichuan New Deal is only the tip of the iceberg, the vast number of pharmaceutical companies only see the trick, and early plans. (E drug manager)